Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Aktis Oncology, Inc.NASDAQ: AKTS
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity of $506.11M in Q1 FY2026
Q1 FY2026 total equity was $506.11M.
Context
- Total equity amounted to 87.7% of total assets at the end of Q1 FY2026.
- Total equity grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- (146.15M) USD
- Year-over-year change
- -66.5%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (146.15M) | -66.5% |
| FY2024 | 2024-12-31 | (87.8M) | -89.6% |
| FY2023 | 2023-12-31 | (46.31M) | -140.8% |
| FY2022 | 2022-12-31 | (19.23M) | — |
Total Equity vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 total equity of $506.11M is the 2nd highest of the 6 companies compared; the peer median is $393.67M.
- Total equity amounts to 87.7% of total assets for AKTS, versus a peer median of 77.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $554.32M | -25.1% | +31.1% | 85.0% | |
| Mar 2026 | $506.11M | — | — | 87.7% | |
| Sep 2026 | $454.3M | +72.1% | +236.5% | 89.9% | |
| Mar 2026 | $393.67M | +4.0% | +4.0% | 36.7% | |
| Mar 2026 | $107.25M | -16.2% | -11.2% | 77.9% | |
| Mar 2026 | $21.2M | -73.2% | -26.8% | 9.7% | |
| Peer median (excluding AKTS) | $393.67M | -16.2% | +4.0% | 77.9% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.